Clinical Trial Update: Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy [Phase 2]

View source ↗

Summary

This is a Phase 2 trial comparing Fostrox plus lenvatinib versus lenvatinib alone in advanced hepatocellular carcinoma after failure of first-line immunotherapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Fostrox
• Lenvatinib (lenvatinib)

Snippet

Sponsor: CHA University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: NOT_YET_RECRUITING